Clinical Improvement of Bullous Pemphigoid with Hyperkeratosis and Palmoplantar Keratoderma in Two Patients Treated with Dupilumab

Giulia Pascolini; Feliciana Mariotti; Anna Pira; Biagio Didona; Giovanni Di Zenzo

doi:10.2340/actadv.v104.41984

Authors

Giulia Pascolini Rare Skin Diseases Center, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Rome, Italy
Feliciana Mariotti Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Rome, Italy
Anna Pira Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Rome, Italy
Biagio Didona Rare Skin Diseases Center, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Rome, Italy
Giovanni Di Zenzo Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell’Immacolata, IDI-IRCCS, Rome, Italy

DOI:

https://doi.org/10.2340/actadv.v104.41984

Keywords:

Bullous pemphigoid, dupilumab, palmoplantar hyperkeratosis

Abstract

Abstract missing (Short communication)

Downloads

Download data is not yet available.

References

Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: clinical manifestations. J Dtsch Dermatol Ges 2011; 9: 844-856.

https://doi.org/10.1111/j.1610-0387.2011.07793.x DOI: https://doi.org/10.1111/j.1610-0387.2011.07793.x

Fania L, Didona D, Pacifico V, Mariotti F, De Luca N, Abeni D, et al. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: three cases. J Dermatol 2018; 45: 1135-1140.

https://doi.org/10.1111/1346-8138.14529 DOI: https://doi.org/10.1111/1346-8138.14529

Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36:1689-1704.

https://doi.org/10.1111/jdv.18220 DOI: https://doi.org/10.1111/jdv.18220

Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol 2023; 159: 953-960.

https://doi.org/10.1001/jamadermatol.2023.2428 DOI: https://doi.org/10.1001/jamadermatol.2023.2428

Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol 2022; 13: 928621.

https://doi.org/10.3389/fimmu.2022.928621 DOI: https://doi.org/10.3389/fimmu.2022.928621

Huang D, Zhang Y, Yu Y, Jiang Y, Kong L, Ding Y, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: a prospective cohort study. Int Immunopharmacol 2023; 125: 111157.

https://doi.org/10.1016/j.intimp.2023.111157 DOI: https://doi.org/10.1016/j.intimp.2023.111157

Miller AC, Temiz LA, Adjei S, Duran MA, Sassmannshausen J, Dominguez A, et al. Treatment of bullous pemphigoid with dupilumab: a case series of 30 patients. J Drugs Dermatol 2024; 23: e144-e148.

https://doi.org/10.36849/JDD.8258 DOI: https://doi.org/10.36849/JDD.8258

Hamada T, Tsuruta D, Fukuda S, Ishii N, Teye K, Numata s, et al. How do keratinizing disorders and blistering disorders overlap? Exp Dermatol 2013; 22: 83-87.

https://doi.org/10.1111/exd.12021 DOI: https://doi.org/10.1111/exd.12021

Razack EM, Premalatha S, Rao NR, Zahra A. Acanthosis palmaris in a patient with bullous pemphigoid. J Am Acad Dermatol 1987; 16: 217-219.

https://doi.org/10.1016/S0190-9622(87)80066-X DOI: https://doi.org/10.1016/S0190-9622(87)80066-X

Bolling MC, Mekkes JR, Goldschmidt WF, Van Noesel CJM, Jonkman MF, Pas HH, et al. Acquired palmoplantar keratoderma and immunobullous disease associated with antibodies to desmocollin 3. Br J Dermatol 2007; 157: 168-173.

https://doi.org/10.1111/j.1365-2133.2007.07920.x DOI: https://doi.org/10.1111/j.1365-2133.2007.07920.x

Mi Z, Sun F, Wang Z, Zhao Q, Pan F, Yan X, et al. Severe atopic eczema treated by dupilumab in a child with keratitis-ichthyosis-deafness syndrome. Australas J Dermatol 2022; 63: 527-529.

https://doi.org/10.1111/ajd.13913 DOI: https://doi.org/10.1111/ajd.13913

Yan S, Wu X, Jiang J, Yu S, Fang X, Yang H, et al. Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation. Front Immunol 2022; 13: 1054422.

https://doi.org/10.3389/fimmu.2022.1054422 DOI: https://doi.org/10.3389/fimmu.2022.1054422

Odorici G, Schenetti C, Marzola E, Monti A, Borghi A, Corazza M. Treatment of Netherton syndrome with dupilumab. J Dtsch Dermatol Ges 2022; 20: 1636-1640.

https://doi.org/10.1111/ddg.14914 DOI: https://doi.org/10.1111/ddg.14914

Wu PC, Dai YX, Li CL, Chen CC, Chang YT, Ma SH. Dupilumab in the treatment of genodermatosis: a systematic review. J Dtsch Dermatol Ges 2023; 21: 7-17.

https://doi.org/10.1111/ddg.14924 DOI: https://doi.org/10.1111/ddg.14924

Galdo G, Fania L. A Netherton syndrome case report: response to dupilumab treatment. Dermatol Ther 2022; 35: e15862.

https://doi.org/10.1111/dth.15862 DOI: https://doi.org/10.1111/dth.15862